References
- Melo JV. The diversity of BCR-ABL Fusion proteins and their relationship to leukemia phenotype. Blood 1996;28:2375–2384.
- Haskovec C, Ponzetto C, Polak J, . P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Brit J Haematol 1998;103:1104–1108.
- Boeckx N, Jansen MW, Haskovec C, . Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligationmediated PCR. Leukemia 2005;19:1292–1295.
- ShafferLG, SlovakML, CampbellLJ. ISCN (2009): International System of Human Cytogenetic Nomenclature. Basel: S Karger AG; 2009.
- Goldman JM. Advances in CML. Clin Adv Hematol Oncol 2007; 5:270–292.
- Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808–4817.
- Ottmann OG, Druker BJ, Sawyers CL, . A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acutelymphoid leukemias. Blood 2002; 100:1965–1971.
- Guilhot F, Apperley J, Kim DW, . Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib resistant or intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143–4150.
- Weerkamp F, Dekking E, Ng YY, . Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009;23:1106–1117.
- Raponi S, De Propris MS, Wai H, . An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia. Haematologica 2009;94:1767–1770.
- Xu W, Li JY, Pan JL, . Interphase fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. Int J Hematol 2007;85:430–436.
- Yu-jie Wu, Yu Zhu, Si-xuan Qian, Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003;17:2318–2357.
- Primo D, Sanchez ML, Espinosa AB, . Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Brit J Haematol 2006;132:736–739.
- Hamilton A, Elrick L, Myssina S, . BCR-ABL activity and its response to drugs can be determined in CD34+CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006;20:1035–1039.